JP2002363102A5 - - Google Patents

Download PDF

Info

Publication number
JP2002363102A5
JP2002363102A5 JP2002100404A JP2002100404A JP2002363102A5 JP 2002363102 A5 JP2002363102 A5 JP 2002363102A5 JP 2002100404 A JP2002100404 A JP 2002100404A JP 2002100404 A JP2002100404 A JP 2002100404A JP 2002363102 A5 JP2002363102 A5 JP 2002363102A5
Authority
JP
Japan
Prior art keywords
use according
administered
drug
transfer agent
dosing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002100404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002363102A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2002363102A publication Critical patent/JP2002363102A/ja
Publication of JP2002363102A5 publication Critical patent/JP2002363102A5/ja
Pending legal-status Critical Current

Links

JP2002100404A 2001-04-03 2002-04-02 新形成細胞の細胞消滅死を誘導する方法 Pending JP2002363102A (ja)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US28074801P 2001-04-03 2001-04-03
US60/280748 2001-04-03
US28171201P 2001-04-06 2001-04-06
US28171301P 2001-04-06 2001-04-06
US28171001P 2001-04-06 2001-04-06
US28171101P 2001-04-06 2001-04-06
US60/281710 2001-04-06
US60/281712 2001-04-06
US60/281711 2001-04-06
US60/281713 2001-04-06
US28493401P 2001-04-20 2001-04-20
US28493301P 2001-04-20 2001-04-20
US60/284934 2001-04-20
US60/284933 2001-04-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009022892A Division JP5232678B2 (ja) 2001-04-03 2009-02-03 新形成細胞の細胞消滅死を誘導する方法

Publications (2)

Publication Number Publication Date
JP2002363102A JP2002363102A (ja) 2002-12-18
JP2002363102A5 true JP2002363102A5 (enExample) 2005-07-21

Family

ID=27569569

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002100404A Pending JP2002363102A (ja) 2001-04-03 2002-04-02 新形成細胞の細胞消滅死を誘導する方法
JP2009022892A Expired - Fee Related JP5232678B2 (ja) 2001-04-03 2009-02-03 新形成細胞の細胞消滅死を誘導する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009022892A Expired - Fee Related JP5232678B2 (ja) 2001-04-03 2009-02-03 新形成細胞の細胞消滅死を誘導する方法

Country Status (5)

Country Link
US (1) US20030027818A1 (enExample)
EP (2) EP1247524B1 (enExample)
JP (2) JP2002363102A (enExample)
CA (2) CA2692295C (enExample)
ES (2) ES2562827T3 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236794B2 (en) 2003-09-29 2012-08-07 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070275955A1 (en) * 1997-07-31 2007-11-29 Ed. Geistlich Soehne Ag Method of treating tumors
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US8304390B2 (en) * 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US8030301B2 (en) * 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US6821968B2 (en) 2001-09-26 2004-11-23 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Stable taurolidine electrolyte solutions
US7345039B2 (en) * 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US7892530B2 (en) * 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
WO2002044394A2 (en) * 2000-11-29 2002-06-06 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
US20030092707A1 (en) * 2001-10-19 2003-05-15 Redmond H. Paul Treatment of breast cancer
US20090123428A1 (en) * 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
EP2353389B1 (en) * 2003-04-21 2015-11-04 Epeius Biotechnologies Corporation Compositions for treating disorders
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
KR20080074143A (ko) * 2005-11-29 2008-08-12 노파르티스 아게 퀴놀리논 제제
EP1976531B1 (en) 2006-01-06 2011-11-09 Ed. Geistlich Söhne AG für Chemische Industrie Irradiated compositions and treatment of cancers with radiation in combination with taurolidine and/or taurultam
RU2468796C2 (ru) * 2006-09-07 2012-12-10 Эд. Гайстлих Зёне Аг Фюр Хемише Индустри Способ лечения рака костей
ES2614878T3 (es) * 2010-06-01 2017-06-02 Geistlich Pharma Ag Métodos y composiciones para terapia farmacéutica oral
CA2999973A1 (en) * 2015-08-31 2017-03-09 Cormedix Inc. Delivery of active agents using nanofiber webs
US20190381060A1 (en) 2016-01-11 2019-12-19 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
CN113347976A (zh) * 2018-08-28 2021-09-03 科医公司 用牛磺罗定水解产物进行的神经母细胞瘤治疗
WO2020047530A1 (en) * 2018-08-31 2020-03-05 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
US20220323452A1 (en) * 2019-05-22 2022-10-13 Geistlich Pharma Ag Methods and compositions for inhibiting gapdh

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210083A (en) 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
GB8617482D0 (en) 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
GB9005856D0 (en) 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions
GB9015108D0 (en) 1990-07-09 1990-08-29 Geistlich Soehne Ag Chemical compositions
AU641529B2 (en) * 1990-07-30 1993-09-23 Bloomfield D.A. Zwitterionic compounds and their N-halo derivatives for use in the treatment of clinical conditions
GB9600426D0 (en) * 1996-01-10 1996-03-13 Ed Geistlich Sohne A G Compositions
US5858990A (en) * 1997-03-04 1999-01-12 St. Elizabeth's Medical Center Fas ligand compositions for treatment of proliferative disorders
NZ500779A (en) 1997-05-20 2001-06-29 Galenica Pharmaceuticals Inc Triterpene saponin analogs having adjuvant and immunostimulatory activity
US6303596B1 (en) * 1997-05-22 2001-10-16 Oklahoma Medical Research Foundation Use of taurolidine for treatment of leukemias
GB9716219D0 (en) * 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
US6479481B1 (en) * 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
EP1246617B1 (en) * 1999-12-06 2006-09-13 Rhode Island Hospital Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of ovarian cancer
CA2363973C (en) * 2000-11-28 2009-03-10 Ed. Geistlich Sohne Ag Fur Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236794B2 (en) 2003-09-29 2012-08-07 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma

Similar Documents

Publication Publication Date Title
JP2009138003A5 (enExample)
EP3173100B1 (en) Therapeutic combination comprising a cdks inhibitor and oxaliplatin
CA2379734A1 (en) Treatment of cancers
AU726089B2 (en) Use of pyrimidine derivatives for the prevention of cancer, on their own or in combination with other therapeutic measures
JP2007515469A5 (enExample)
FI3463345T3 (fi) Farmaseuttisia yhdistelmiä
US20210353627A1 (en) Novel quinazoline egfr inhibitors
EP1201247B1 (en) Treatment of metastatic renal cell carcinoma
JPH05500973A (ja) 化学的組成物
JP2005517040A5 (enExample)
JPH05506431A (ja) リューマチ疾患治療のためのスラミンの使用
MX2008016125A (es) Compuestos organicos.
DICK et al. Reserpine-Digitalis Toxicity: Case Reports of Cardiac Arrhythmias Occurring During Reserpine-Digitalis Therapy and a Review of the Literature with Supporting Animal Experiments
CN114469955B (zh) 喹唑啉衍生物在制备预防和/或治疗胃肠道疾病药物中的应用
JP2002326936A (ja) 腫瘍転移および癌の治療における５−フルオロウラシルの有効性の増強
Love et al. Glucagon therapy in the treatment of symptomatic bradycardia
CA2482687A1 (en) Treatment of mesothelioma
CN101185627A (zh) 一种治疗实体肿瘤的尼罗替尼缓释植入剂
JPH06505741A (ja) 非小細胞肺癌の治療
JP2020512408A5 (enExample)
CN113925850A (zh) D-甘露糖促进三阴性乳腺癌的免疫治疗和放疗的用途
Moertel et al. IN PATIENTS WITH GASTROINTESTINAL CARCINOMA 1, 2, 3
CN101181232B (zh) 一种治疗实体肿瘤的马赛替尼缓释植入剂
JP2004533434A5 (enExample)
CN106466305A (zh) 二甲双胍用于制备治疗和/或预防头颈鳞癌药物中的用途及药物组合物